791 related articles for article (PubMed ID: 25049410)
1. RNA-directed gene editing specifically eradicates latent and prevents new HIV-1 infection.
Hu W; Kaminski R; Yang F; Zhang Y; Cosentino L; Li F; Luo B; Alvarez-Carbonell D; Garcia-Mesa Y; Karn J; Mo X; Khalili K
Proc Natl Acad Sci U S A; 2014 Aug; 111(31):11461-6. PubMed ID: 25049410
[TBL] [Abstract][Full Text] [Related]
2. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
Soriano V
AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
[TBL] [Abstract][Full Text] [Related]
3. CRISPR/gRNA-directed synergistic activation mediator (SAM) induces specific, persistent and robust reactivation of the HIV-1 latent reservoirs.
Zhang Y; Yin C; Zhang T; Li F; Yang W; Kaminski R; Fagan PR; Putatunda R; Young WB; Khalili K; Hu W
Sci Rep; 2015 Nov; 5():16277. PubMed ID: 26538064
[TBL] [Abstract][Full Text] [Related]
4. Targeted Chromatinization and Repression of HIV-1 Provirus Transcription with Repurposed CRISPR/Cas9.
Olson A; Basukala B; Lee S; Gagne M; Wong WW; Henderson AJ
Viruses; 2020 Oct; 12(10):. PubMed ID: 33053801
[TBL] [Abstract][Full Text] [Related]
5. Viral diversity is an obligate consideration in CRISPR/Cas9 designs for targeting the HIV reservoir.
Roychoudhury P; De Silva Feelixge H; Reeves D; Mayer BT; Stone D; Schiffer JT; Jerome KR
BMC Biol; 2018 Jul; 16(1):75. PubMed ID: 29996827
[TBL] [Abstract][Full Text] [Related]
6. CRISPR/Cas9 Ablation of Integrated HIV-1 Accumulates Proviral DNA Circles with Reformed Long Terminal Repeats.
Lai M; Maori E; Quaranta P; Matteoli G; Maggi F; Sgarbanti M; Crucitta S; Pacini S; Turriziani O; Antonelli G; Heeney JL; Freer G; Pistello M
J Virol; 2021 Nov; 95(23):e0135821. PubMed ID: 34549986
[TBL] [Abstract][Full Text] [Related]
7. CRISPR/Cas9-mediated genome editing of Epstein-Barr virus in human cells.
Yuen KS; Chan CP; Wong NM; Ho CH; Ho TH; Lei T; Deng W; Tsao SW; Chen H; Kok KH; Jin DY
J Gen Virol; 2015 Mar; 96(Pt 3):626-636. PubMed ID: 25502645
[TBL] [Abstract][Full Text] [Related]
8. Negative Feedback Regulation of HIV-1 by Gene Editing Strategy.
Kaminski R; Chen Y; Salkind J; Bella R; Young WB; Ferrante P; Karn J; Malcolm T; Hu W; Khalili K
Sci Rep; 2016 Aug; 6():31527. PubMed ID: 27528385
[TBL] [Abstract][Full Text] [Related]
9. Potent and Targeted Activation of Latent HIV-1 Using the CRISPR/dCas9 Activator Complex.
Saayman SM; Lazar DC; Scott TA; Hart JR; Takahashi M; Burnett JC; Planelles V; Morris KV; Weinberg MS
Mol Ther; 2016 Mar; 24(3):488-98. PubMed ID: 26581162
[TBL] [Abstract][Full Text] [Related]
10. Broad-Spectrum and Personalized Guide RNAs for CRISPR/Cas9 HIV-1 Therapeutics.
Dampier W; Sullivan NT; Mell JC; Pirrone V; Ehrlich GD; Chung CH; Allen AG; DeSimone M; Zhong W; Kercher K; Passic S; Williams JW; Szep Z; Khalili K; Jacobson JM; Nonnemacher MR; Wigdahl B
AIDS Res Hum Retroviruses; 2018 Nov; 34(11):950-960. PubMed ID: 29968495
[TBL] [Abstract][Full Text] [Related]
11. CRISPR-Cas9 Mediated Exonic Disruption for HIV-1 Elimination.
Herskovitz J; Hasan M; Patel M; Blomberg WR; Cohen JD; Machhi J; Shahjin F; Mosley RL; McMillan J; Kevadiya BD; Gendelman HE
EBioMedicine; 2021 Nov; 73():103678. PubMed ID: 34774454
[TBL] [Abstract][Full Text] [Related]
12. The Impact of HIV-1 Genetic Diversity on CRISPR-Cas9 Antiviral Activity and Viral Escape.
Darcis G; Binda CS; Klaver B; Herrera-Carrillo E; Berkhout B; Das AT
Viruses; 2019 Mar; 11(3):. PubMed ID: 30871200
[TBL] [Abstract][Full Text] [Related]
13. Clustered regularly interspaced palindromic repeats-cas9-based strategies towards HIV eradication: A literature review.
Miranda AV; Wiyono L; Nurachman LA
J Pak Med Assoc; 2021 Feb; 71(Suppl 2)(2):S134-S139. PubMed ID: 33785958
[TBL] [Abstract][Full Text] [Related]
14. Synthetic gRNA/Cas9 Ribonucleoprotein Inhibits HIV Reactivation and Replication.
Khanal S; Cao D; Zhang J; Zhang Y; Schank M; Dang X; Nguyen LNT; Wu XY; Jiang Y; Ning S; Zhao J; Wang L; Gazzar ME; Moorman JP; Yao ZQ
Viruses; 2022 Aug; 14(9):. PubMed ID: 36146709
[TBL] [Abstract][Full Text] [Related]
15. CRISPR-mediated Activation of Latent HIV-1 Expression.
Limsirichai P; Gaj T; Schaffer DV
Mol Ther; 2016 Mar; 24(3):499-507. PubMed ID: 26607397
[TBL] [Abstract][Full Text] [Related]
16. CRISPR/Cas9: a tool to eradicate HIV-1.
Bhowmik R; Chaubey B
AIDS Res Ther; 2022 Dec; 19(1):58. PubMed ID: 36457057
[TBL] [Abstract][Full Text] [Related]
17. Harnessing the CRISPR/Cas9 system to disrupt latent HIV-1 provirus.
Ebina H; Misawa N; Kanemura Y; Koyanagi Y
Sci Rep; 2013; 3():2510. PubMed ID: 23974631
[TBL] [Abstract][Full Text] [Related]
18. Elimination of HIV-1 Genomes from Human T-lymphoid Cells by CRISPR/Cas9 Gene Editing.
Kaminski R; Chen Y; Fischer T; Tedaldi E; Napoli A; Zhang Y; Karn J; Hu W; Khalili K
Sci Rep; 2016 Mar; 6():22555. PubMed ID: 26939770
[TBL] [Abstract][Full Text] [Related]
19. Targeted HIV-1 Latency Reversal Using CRISPR/Cas9-Derived Transcriptional Activator Systems.
Bialek JK; Dunay GA; Voges M; Schäfer C; Spohn M; Stucka R; Hauber J; Lange UC
PLoS One; 2016; 11(6):e0158294. PubMed ID: 27341108
[TBL] [Abstract][Full Text] [Related]
20. Genome scale screening identification of SaCas9/gRNAs for targeting HIV-1 provirus and suppression of HIV-1 infection.
Wang Q; Liu S; Liu Z; Ke Z; Li C; Yu X; Chen S; Guo D
Virus Res; 2018 May; 250():21-30. PubMed ID: 29625148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]